Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral Edaravone in ALS Patients With Gastrostomy
NCT04254913Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point at 24 hours, Maximum Plasma Concentration at 24 hours and 10 more. Started Jan 2020; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04254913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254913.